128 related articles for article (PubMed ID: 30482852)
1. Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
Sinik L; Minson KA; Tentler JJ; Carrico J; Bagby SM; Robinson WA; Kami R; Burstyn-Cohen T; Eckhardt SG; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Mol Cancer Ther; 2019 Feb; 18(2):278-288. PubMed ID: 30482852
[TBL] [Abstract][Full Text] [Related]
2. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
[TBL] [Abstract][Full Text] [Related]
3. ERK5 is activated by oncogenic BRAF and promotes melanoma growth.
Tusa I; Gagliardi S; Tubita A; Pandolfi S; Urso C; Borgognoni L; Wang J; Deng X; Gray NS; Stecca B; Rovida E
Oncogene; 2018 May; 37(19):2601-2614. PubMed ID: 29483645
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells.
Misek SA; Newbury PA; Chekalin E; Paithankar S; Doseff AI; Chen B; Gallo KA; Neubig RR
Mol Pharmacol; 2022 Jan; 101(1):1-12. PubMed ID: 34732527
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.
Porcelli L; Guida G; Quatrale AE; Cocco T; Sidella L; Maida I; Iacobazzi RM; Ferretta A; Stolfa DA; Strippoli S; Guida S; Tommasi S; Guida M; Azzariti A
J Transl Med; 2015 Jan; 13():26. PubMed ID: 25623468
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF
Smith LK; Parmenter T; Gould CM; Madhamshettiwar PB; Sheppard KE; Simpson KJ; McArthur GA
Sci Data; 2020 Oct; 7(1):339. PubMed ID: 33046726
[TBL] [Abstract][Full Text] [Related]
7. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.
Hayes TK; Luo F; Cohen O; Goodale AB; Lee Y; Pantel S; Bagul M; Piccioni F; Root DE; Garraway LA; Meyerson M; Johannessen CM
Cancer Res; 2019 May; 79(9):2352-2366. PubMed ID: 30819666
[TBL] [Abstract][Full Text] [Related]
8. BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.
Miele E; Abballe L; Spinelli GP; Besharat ZM; Catanzaro G; Chiacchiarini M; Vacca A; Po A; Capalbo C; Ferretti E
BMC Cancer; 2020 Feb; 20(1):129. PubMed ID: 32066410
[TBL] [Abstract][Full Text] [Related]
9. Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma.
Kim J; Archer PA; Manspeaker MP; Avecilla ARC; Pollack BP; Thomas SN
J Control Release; 2023 May; 357():655-668. PubMed ID: 37080489
[TBL] [Abstract][Full Text] [Related]
10. NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth.
Cai C; Tu J; Najarro J; Zhang R; Fan H; Zhang FQ; Li J; Xie Z; Su R; Dong L; Arellano N; Ciboddo M; Elf SE; Gao X; Chen J; Wu R
Mol Cancer Res; 2024 Apr; 22(4):386-401. PubMed ID: 38294692
[TBL] [Abstract][Full Text] [Related]
11. Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review.
Yu N; Raslan OA; Lee HS; Theeler BJ; Raafat TA; Fragoso R; Shahlaie K; Aboud O
CNS Oncol; 2024 Jan; 13(1):CNS106. PubMed ID: 38348829
[TBL] [Abstract][Full Text] [Related]
12. Targeting the receptor tyrosine kinase MerTK shows therapeutic value in gastric adenocarcinoma.
Wirsik NM; Chen M; He L; Yasar U; Gaukel J; Quaas A; Nienhüser H; Leugner E; Yuan S; Schleussner N; Jung JO; Plücker JS; Schneider M; Schmidt T
Cancer Med; 2024 Apr; 13(7):e6866. PubMed ID: 38545840
[TBL] [Abstract][Full Text] [Related]
13. Metabolic stress regulates ERK activity by controlling KSR-RAF heterodimerization.
Verlande A; Krafčíková M; Potěšil D; Trantírek L; Zdráhal Z; Elkalaf M; Trnka J; Souček K; Rauch N; Rauch J; Kolch W; Uldrijan S
EMBO Rep; 2018 Feb; 19(2):320-336. PubMed ID: 29263201
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing.
Mukhtar AB; Morgan HJ; Gibbs A; Davies GE; Lovatt C; Patel GK
Br J Dermatol; 2024 Apr; 190(5):729-739. PubMed ID: 38288865
[TBL] [Abstract][Full Text] [Related]
15. ERK mediates interferon gamma-induced melanoma cell death.
Champhekar A; Heymans R; Saco J; Turon Font G; Gonzalez C; Gao A; Pham J; Lee J; Maryoung R; Medina E; Campbell KM; Karin D; Austin D; Damioseaux R; Ribas A
Mol Cancer; 2023 Oct; 22(1):165. PubMed ID: 37803324
[TBL] [Abstract][Full Text] [Related]
16. Loss of Ambra1 promotes melanoma growth and invasion.
Di Leo L; Bodemeyer V; Bosisio FM; Claps G; Carretta M; Rizza S; Faienza F; Frias A; Khan S; Bordi M; Pacheco MP; Di Martino J; Bravo-Cordero JJ; Daniel CJ; Sears RC; Donia M; Madsen DH; Guldberg P; Filomeni G; Sauter T; Robert C; De Zio D; Cecconi F
Nat Commun; 2021 May; 12(1):2550. PubMed ID: 33953176
[TBL] [Abstract][Full Text] [Related]
17. The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells.
Chen Y; Sang Y; Li S; Xue J; Chen M; Hong S; Lv W; Sehgal K; Xiao H; Liu R
Transl Oncol; 2024 May; 45():101991. PubMed ID: 38728872
[TBL] [Abstract][Full Text] [Related]
18. Light-Activatable Photocaged UNC2025 for Triggering TAM Kinase Inhibition in Bladder Cancer.
Breton-Patient C; Billotte S; Duchambon P; Fontaine G; Bombard S; Piguel S
Chembiochem; 2024 Apr; 25(8):e202300855. PubMed ID: 38363151
[TBL] [Abstract][Full Text] [Related]
19. Targeting malignant melanoma cells expressing the protein CD20 enhances BRAF-targeted treatment.
Br J Dermatol; 2024 Apr; 190(5):e58. PubMed ID: 38630926
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
